Ocular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double

Dow Jones

May 05, 2025

By Kelly Cloonan

Shares of Ocular Therapeutix fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled.

The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months.

The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share.

Revenue fell 28% to $10.7 million. Analysts expected $17 million.

The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier.

The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 05, 2025 11:50 ET (15:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533453470"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533453470\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533453470?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-05 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533453470","market":"nz","top_or_hot":-1,"title":"Ocular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled. \n</p>\n<p>\n  The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months. \n</p>\n<p>\n  The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share. \n</p>\n<p>\n  Revenue fell 28% to $10.7 million. Analysts expected $17 million. \n</p>\n<p>\n  The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier. \n</p>\n<p>\n  The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2025 11:50 ET (15:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-05 23:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled. \n</p>\n<p>\n  The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months. \n</p>\n<p>\n  The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share. \n</p>\n<p>\n  Revenue fell 28% to $10.7 million. Analysts expected $17 million. \n</p>\n<p>\n  The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier. \n</p>\n<p>\n  The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2025 11:50 ET (15:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533453470","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533453470","pubTimestamp":1746460200,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Ocular Therapeutix fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled.The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months.The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share.Revenue fell 28% to $10.7 million. Analysts expected $17 million.The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier.The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OCUL":"Ocular Therapeutix"},"translate_title":"Ocular Therapeutix股价下跌，第一季度未达目标，研发费用翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Ocular Therapeutix fell after the company's first-quarter earnings and revenue missed Wall Street's expectations and its research-and-development expenses doubled. \n\n\n  The stock fell 11% to $7.87 on Monday. Shares have risen 28% in the past 12 months. \n\n\n  The company on Monday posted a loss of $64.1 million, or 38 cents a share, compared with $64.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 29 cents a share. \n\n\n  Revenue fell 28% to $10.7 million. Analysts expected $17 million. \n\n\n  The company's research-and-development expenses more than doubled to $42.9 million, up from $20.7 million in the same period a year earlier. \n\n\n  The increase reflects higher overall clinical expenses associated with its SOL-1 and SOL-R Phase 3 trials, as well as additional personnel and professional services to support the trials, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2025 11:50 ET (15:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}